Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028 [0.03%]
预计纳入2026年谈判、2028年实施的 Medicare 药品清单
Emma M Cousin,Kristi Martin,Ryan N Hansen et al.
Emma M Cousin et al.
Background: The 2028 incorporation of Part B drugs into the Medicare Drug Price Negotiation Program, established by the Inflation Reduction Act (IRA), introduces several unique challenges. The Centers for Medicare & Medic...
Unmanaged depression and chronic disease medication adherence in Medicare Advantage beneficiaries: A claims-based analysis [0.03%]
医疗保险优势受益人未加干预的抑郁与慢性疾病药物治疗顺应性：基于索赔数据的分析
Danny Nguyen,Andy Bowe,Alayna Stepter et al.
Danny Nguyen et al.
Medication utilization patterns among patients with rheumatoid arthritis and coexisting autoimmune conditions [0.03%]
合并自身免疫性疾病的类风湿关节炎患者中的药物利用模式
Jonathan P DeShazo,Erick Moyneur,Djeneba Audrey Djibo et al.
Jonathan P DeShazo et al.
Background: Rheumatoid arthritis (RA) is the most common inflammatory joint disease worldwide. T-cell inhibitors, tumor necrosis factor inhibitors, interleukin inhibitors (ILIs), Janus kinase inhibitors, and B-cell deplet...
Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non-small cell lung cancer [0.03%]
老年转移性非小细胞肺癌患者一线使用阿特朱单抗、尼伏鲁单抗和派姆单抗的现实生存对比研究
Xiangzhong Xue,Matthew Loop,Brandon Johnson et al.
Xiangzhong Xue et al.
Background: Although immune checkpoint inhibitors (ICIs) have significantly improved overall survival (OS) for patients with metastatic non-small cell lung cancer (mNSCLC), there is a paucity of comparative effectiveness ...
The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United States [0.03%]
直接抗病毒疗法与慢性丙型肝炎病毒感染患者医疗保健利用和成本的关系：美国真实世界研究的系统评价
Seyed M Karimi,Sepideh Poursafargholi,Yathreb Bayan Mohamed et al.
Seyed M Karimi et al.
Background: Hepatitis C is a viral infection that can lead to severe liver damage, liver cancer, and death. However, it has remained a major public health concern, affecting millions worldwide, including over 2.4 million ...
Pharmacist care for attention-deficit/hyperactivity disorder electronic medication refills: A cluster randomized trial [0.03%]
注意缺陷多动障碍的药师关怀与电子处方续方：分层群组随机试验
Tracy A Lieu,Daniel Parry,Andrew deLaunay et al.
Tracy A Lieu et al.
Background: During the pandemic, the US government loosened restrictions on telemedicine prescribing for controlled substance refills. Parent requests for attention-deficit/hyperactivity disorder (ADHD) medication refills...
Randomized Controlled Trial
Journal of managed care & specialty pharmacy. 2025 Nov;31(11):1156-1165. DOI:10.18553/jmcp.2025.31.11.1156 2025
Patient engagement in managed care pharmacy: Putting policy into practice [0.03%]
医药保健药房中的患者参与度：付诸行动的政策
Joe Vandigo,Kimberly Lenz,Emily Grace Tsiao et al.
Joe Vandigo et al.
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiation [0.03%]
停止透明质酸酶的跳跃以维护医疗保险药物价格谈判的完整性
John Kim,Aaron S Kesselheim,Benjamin N Rome
John Kim
The Inflation Reduction Act empowered Medicare to negotiate drug prices for certain drugs, but the initial program guidance treated fixed-dose combination drugs separately, which would allow manufacturers of biologics to launch subcutaneous...
Trends in delivery of comprehensive medication reviews by race and ethnicity, 2013-2021 [0.03%]
2013至2021年按种族和族裔划分的全面药物回顾服务趋势
Devika A Shenoy,Lauren Wilson,Joel Farley et al.
Devika A Shenoy et al.
Background: Comprehensive medication reviews (CMRs) are a cornerstone of medication therapy management (MTM) for millions of Medicare Part D beneficiaries, designed to optimize medication use and health outcomes. However,...
Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis [0.03%]
基于真实世界数据分析的接受嵌合抗原受体T细胞治疗弥漫大B细胞淋巴瘤患者在不同医疗环境下的人力和经济资源使用情况
Anik R Patel,Ken Hasegawa,Shivani Pandya et al.
Anik R Patel et al.
Background: Chimeric antigen receptor T-cell (CAR T) therapies have transformed the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Receiving CAR T infusion in the hospital may be limited by const...